Elucid is set to spotlight its PlaqueIQ™ platform at SCCT 2025, bringing attention to a groundbreaking advancement in cardiovascular diagnostics. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis software that bases its assessment on objective histology rather than subjective visual interpretations from coronary computed tomography angiography (CCTA). This innovation uses AI to quantify and classify plaque morphology at the lesion level, providing unprecedented insight into plaque composition, including lipid-rich necrotic core. This approach aligns with the gold standard in histological analysis and represents a paradigm shift in how clinicians assess coronary artery disease.

The primary purpose of PlaqueIQ is to enhance diagnostic precision and enable truly personalized cardiac care. By analyzing imaging data with histology-based accuracy, the software supports physicians in stratifying risk and tailoring interventions to the individual patient rather than relying on generalized, population-level estimates. Clinicians can make better-informed decisions regarding therapeutic strategies, such as medication or intervention, based on the actual plaque burden and morphology. Its user-friendly design and integration with clinical workflows make it a valuable tool in both preventative cardiology and acute care settings.

Elucid’s presence at SCCT 2025, including keynote sessions, symposiums, and live demonstrations, underscores the platform's growing clinical relevance and its potential to redefine plaque assessment. With its unique combination of AI, objective histological validation, and real-world utility, PlaqueIQ empowers cardiologists to proactively address the root causes of heart disease and mitigate the risk of major cardiac events. As the demand for precision medicine continues to rise, innovations like PlaqueIQ are poised to play a central role in transforming cardiovascular care and improving long-term outcomes.